CHRISTOPHER GAKWA: Open Payments
NPI 1205355831 · BOISE, ID. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$699 in 35 payments from 10 companies in 2025. Trend: 2023 $133 · 2024 $154 · 2025 $699
Food & beverage: $699
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 7 | $208 |
| Otsuka America Pharmaceutical, Inc. | 11 | $180 |
| E.R. Squibb & Sons, L.L.C. | 5 | $101 |
| ABBVIE INC. | 3 | $43 |
| Janssen Pharmaceuticals, Inc | 2 | $38 |
| Alkermes, Inc. | 2 | $31 |
| Lundbeck LLC | 2 | $30 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $30 |
| Vanda Pharmaceuticals Inc. | 1 | $26 |
| Teva Pharmaceuticals USA, Inc. | 1 | $14 |
Products named: INGREZZA, REXULTI, COBENFY, ABILIFY ASIMTUFII, VRAYLAR, INVEGA SUSTENNA, TRINTELLIX, FANAPT.
Industry payments across ID — which companies pay providers there.
